Core Insights - Bio-Path Holdings, Inc. has progressed its Phase 1/1b clinical trial for BP1002, targeting refractory/relapsed acute myeloid leukemia (AML), to the fourth higher dose cohort of 90 mg/m2, indicating promising patient responses [2][3] Company Overview - Bio-Path Holdings, Inc. is a biotechnology company focused on developing targeted nucleic acid cancer and obesity drugs using its proprietary DNAbilize® liposomal delivery and antisense technology [2][6] - The company’s lead product candidate, BP1001, is in a Phase 2 study for blood cancers, while BP1002 is being evaluated for blood cancers and solid tumors, including AML [6] Clinical Trial Progress - The ongoing Phase 1/1b clinical trial has shown a meaningful patient response, with one patient in the third cohort experiencing stable disease and a significant reduction in blast count after one treatment cycle [3] - The trial is being conducted at several leading cancer centers in the U.S., including Weill Medical College of Cornell University and MD Anderson Cancer Center [4][5] - The approved treatment cycle consists of two doses per week over four weeks, totaling eight doses administered over twenty-eight days [4] Treatment Context - The current standard of care for AML patients not eligible for intensive chemotherapy is venetoclax, which many patients become resistant to, leading to poor prognosis [3] - BP1002 aims to target Bcl-2 at the mRNA level, potentially overcoming resistance mechanisms associated with venetoclax treatment [3]
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia